Pfizer and BioNTech said Friday that a COVID-19 vaccine could be tweaked and produced within 100 days to counter a "vaccine-escape" variant.
The World Health Organization identified the B.1.1.529 strain found in southern Africa as a highly transmissible "variant of concern." The WHO labeled the strain with the Greek letter omicron.
In an emailed statement to FOX Business, Pfizer said the vaccine-makers are "remaining vigilant" and "constantly conducting surveillance efforts focused on monitoring for emerging variants that potentially escape protection from our vaccine."
GOAL: $250 to $500 Every Single Day the Market is Open…Like Clockwork!
Discover this Simple, 4-Step Process, Fully Disclosed BLUEPRINT for yourself.
"As always, we will continue to follow the science as we examine the best approaches to protecting people against COVID-19," Pfizer wrote. "In the event that vaccine-escape variant emerges, Pfizer and BioNTech expect to be able to develop and produce a tailor-made vaccine against that variant in approximately 100 days, subject to regulatory approval."
Pfizer CEO Albert Bourla has previously pledged the companies could develop a new vaccine within the same timeframe.
"So far, data saw that none of the existing variant strains has escaped the protection provided by our vaccine. I repeat: none. Not one," he said at the White House in June. "Still, we have built a process to develop, within 100 days, a new vaccine if needed. God forbid."
In a separate statement to FOX Business, a spokesperson said that BioNTech has immediately initiated investigations on the variant.
"The variant differs significantly from previously observed variants as it has additional mutations located in the spike protein. We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally," the spokesperson wrote.
"Pfizer and BioNTech have taken actions months ago to be able to adapt the mRNA vaccine within six weeks and ship initial batches within 100 days in the event of an escape variant. To that end, the companies have begun clinical trials with variant-specific vaccines (alpha and delta) to collect safety and tolerability data that can be provided to regulators as part of the blueprint studies in the event of [a] needed variant-specific vaccine," the company said.
Johnson & Johnson also told FOX Business that the company was testing the effectiveness of the Johnson & Johnson Janssen vaccine against the B.1.1.529 variant.
"We are closely monitoring newly emerging COVID-19 virus strains with variations in the SARS-CoV-2 spike protein and are already testing the effectiveness of our vaccine against the new and rapidly spreading variant first detected in southern Africa," a spokesperson wrote in a Friday email. "We remain steadfast in the benefit the Johnson & Johnson COVID-19 vaccine will provide to millions around the world."
I hope this article helps in your trading strategy.